Ovarian Cancer Immunotherapy en Route: IL9 Inhibits Growth of Ovarian Cancer and Upregulates its Expression of Ox40L and 4-1BBL

Objective: Ovarian cancer is the deadliest of all gynecologic tumors. Current treatment methods include debulking surgery with chemotherapy, however even with treatment, the five-year survival rate is below 45%. Cancer immunotherapy is an innovative treatment option being highly researched. Interleukins (ILs) are signaling molecules used by the human immune system to assist in detecting and destroying cancer cells. The ability of tumor cells to evade the immune system is a major challenge we face in fighting cancer. Ox40L/Ox40 and 4-1BBL/4-1BB are key immune costimulatory molecules that increase T cell activation to eliminate tumors. Past research has shown that IL9 has unique influences on various types of cancer, however, its role in ovarian cancer has not yet been assessed. In this study, ovarian cancer cells were treated with IL9 and the expression of Ox40L and 4-1BBL were measured. Methods: A2780 ovarian cancer cells were treated with IL9. Proliferation of ovarian cancer cells was measured by a Clonogenic Survival Assay and Quick Proliferation Assay. RT-PCR was conducted to determine whether IL9 upregulated the costimulatory molecules Ox40L and 4-1BBL. IHC was performed to further investigate IL9 upregulation of Ox40L and 4-1BBL. Results: Treatment of A2780 ovarian cancer cells with IL9 resulted in decreased proliferation of the ovarian cancer cells. By using RT-PCR, it was determined that IL9 treated ovarian cancer cells displayed upregulation of the costimulatory molecules Ox40L and 4-1BBL. Upregulation of OX40L and 4-1BBL was further confirmed by IHC. Conclusions: IL9 inhibited growth of ovarian cancer cells, and IL9 upregulated the key immune costimulatory molecules Ox40L and 4-1BBL. This suggests that increased expression of Ox40L and 4-1BBL may be associated with the inhibitory effect of IL9 on proliferation of ovarian cancer. This study warrants further investigation of the role of Ox40L and 4-1BBL in ovarian cancer growth.

ovarian cancer; interleukins; immunotherapy; costimulatory molecules.

[1] Roett MA, Evans P. Ovarian cancer: an overview. American Family Physician. 2009; 80: 609–616.

[2] Kossaï M, Leary A, Scoazec J, Genestie C. Ovarian Cancer: a Heterogeneous Disease. Pathobiology. 2018; 85: 41–49.

[3] Rooth C. Ovarian cancer: risk factors, treatment and management. British Journal of Nursing. 2013; 22: S23–S30.

[4] Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology. 2017; 41: 3–14.

[5] Odunsi K. Immunotherapy in ovarian cancer. Annals of Oncology. 2017; 28: viii1–viii7.

[6] Grunewald T, Ledermann JA. Targeted Therapies for Ovarian Cancer. Best Practice & Research: Clinical Obstetrics & Gynaecology. 2017; 41: 139–152.

[7] Elmslie RE, Dow SW, Ogilvie GK. Interleukins: Biological Properties and Therapeutic Potential. Journal of Veterinary Internal Medicine. 1991; 5: 283–293.

[8] Yoshimoto T, Morishima N, Okumura M, Chiba Y, Xu M, Mizuguchi J. Interleukins and cancer immunotherapy. Immunotherapy. 2009; 1: 825–844.

[9] Zheng N, Lu Y. Targeting the IL-9 pathway in cancer immunotherapy. Human Vaccines & Immunotherapeutics. 2020; 16: 2333–2340.

[10] Liu X, Hansen DM, Timko NJ, Zhu Z, Ames A, Qin C, et al. Association between interleukin‑33 and ovarian cancer. Oncology Reports. 2019; 41: 1045–1050.

[11] Wan J, Wu Y, Ji X, Huang L, Cai W, Su Z, et al. IL-9 and IL-9- producing cells in tumor immunity. Cell Communication and Signaling. 2020; 18: 50.

[12] Zheng N, Lu Y. Targeting the IL-9 pathway in cancer immunotherapy. Human Vaccines & Immunotherapeutics. 2020; 16: 2333–2340.

[13] Wang W, Liu JR, Zou W. Immunotherapy in Ovarian Cancer. Surgical Oncology Clinics of North America. 2019; 28: 447–464.

[14] Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Frontiers in Immunology. 2020; 11: 577869.

[15] Redmond WL, Weinberg AD. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Critical Reviews in Immunology. 2007; 27: 415–436.

[16] He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, Deng J, et al. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Translational Lung Cancer Research. 2019; 8: 352–366.

[17] Barsoumian HB, Batra L, Shrestha P, Bowen WS, Zhao H Egilmez NK, et al. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells. Cancer Research. 2019; 79: 783–794.

[18] Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018; 131: 39–48.

[19] Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, et al. Monoclonal antibodies against the 4-1BB T-cell activating molecule eradicate established tumors. Nature Medicine. 1997; 3: 682–685.

[20] Krause P, Bruckner M, Uermösi C, Singer E, Groettrup M, Legler DF. Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood. 2009; 113: 2451–2460.

[21] Fang Y, Chen X, Bai Q, Qin C, Mohamud AO, Zhu Z, et al. IL-9 inhibits HTB-72 melanoma cell growth through upregulation of p21 and TRAIL. Journal of Surgical Oncology. 2015; 111: 969–974.

[22] Zhu Z, Davidson KT, Brittingham A, Wakefield MR, Bai Q, Xiao H, et al. Trichomonas vaginalis: a possible foe to prostate cancer. Medical Oncology. 2016; 33: 115.

[23] Ding VA, Zhu Z, Steele TA, Wakefield MR, Xiao H, Balabanov D, et al. The novel role of IL-37 in prostate cancer: evidence as a promising radiosensitizer. Medical Oncology. 2017; 35: 6.

[24] Fang Y, Zhao L, Xiao H, Cook KM, Bai Q, Herrick EJ, et al. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Medical Oncology. 2017; 34: 23.

[25] Chen X, Lu K, Timko NJ, Weir DM, Zhu Z, Qin C, et al. IL-33 notably inhibits the growth of colon cancer cells. Oncology Letters. 2018; 16: 769–774.

[26] Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annual Review of Immunology. 2005; 23: 23–68.

[27] Shao Z, Schwarz H. CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. Journal of Leukocyte Biology. 2011; 89: 21–29.

[28] Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C, et al. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. OncoTargets and Therapy. 2019; 12: 7347–7353.

[29] Lu X. OX40 and OX40L Interaction in Cancer. Current Medicinal Chemistry. 2021; 28: 5659–5673.

[30] Virani NA, Thavathiru E, McKernan P, Moore K, Benbrook DM, Harrison RG. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Letters. 2018; 425: 174–182.

[31] Lu X. OX40 and OX40L Interaction in Cancer. Current Medicinal Chemistry. 2020; 28: 5659–5673.

[32] Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Research. 2013; 73: 7189–7198.

[33] Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Molecular Cancer Therapeutics. 2012; 11: 1062–1070.

[34] Youlin K, Li Z, Xiaodong W, Xiuheng L, Hengchen Z. Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer. Clinical & Developmental Immunology. 2012; 2012: 439235.

[35] Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Reports. 2014; 47: 122–129.

[36] Zhou SN, Ran RZ, Tan LL, Guo H. Current perspectives of SA-

4- 1BBL in immune modulation during cancer. Experimental and Therapeutic Medicine. 2018; 15: 2699–2702.